Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlexander Cohenen_US
dc.contributor.authorSinnadurai Jeyaindranen_US
dc.contributor.authorJae Yeol Kimen_US
dc.contributor.authorKihyuk Parken_US
dc.contributor.authorSuree Sompradeekulen_US
dc.contributor.authorKarmel L. Tambunanen_US
dc.contributor.authorHuyen Tranen_US
dc.contributor.authorI. Chen Tsaien_US
dc.contributor.authorChristopher Warden_US
dc.contributor.authorRaymond Wongen_US
dc.contributor.otherGuy's and St Thomas' NHS Foundation Trusten_US
dc.contributor.otherKuala Lumpur Hospitalen_US
dc.contributor.otherChung-Ang University, College of Medicineen_US
dc.contributor.otherDaegu Catholic University Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversitas Indonesiaen_US
dc.contributor.otherAlfred Hospitalen_US
dc.contributor.otherMonash Universityen_US
dc.contributor.otherShow-Chwan Memorial Hospital Taiwanen_US
dc.contributor.otherKolling Institute of Medical Researchen_US
dc.contributor.otherPrince of Wales Hospital Hong Kongen_US
dc.identifier.citationThrombosis Research. Vol.136, No.2 (2015), 196-207en_US
dc.description.abstract© 2015 Elsevier Ltd. All rights reserved. Pulmonary embolism (PE) is the principal preventable cause of in-hospital deaths. Prevalence of PE in Asians is uncertain but undoubtedly underestimated. Asians and Caucasians have similar non-genetic risk factors for PE, and there is mounting evidence that PE affects Asians much more commonly than previously supposed; incidence, especially among high-risk patients, may approach that in Caucasians. Furthermore, PE incidence in Asia is increasing, due to both increased ascertainment, and also population ageing and growing numbers of patients with predisposing risk factors. Despite being warranted, thromboprophylaxis for high-risk patients is not routine in Pacific Asian countries/regions. There also appears to be scope to implement venous thromboembolism (VTE) management guidelines more assiduously. Anticoagulants, primarily heparins and warfarin, have been the mainstays of VTE management for years; however, these agents have limitations that complicate routine use. The complexity of current guidelines has been another barrier to applying evidence-based recommendations in everyday practice. Updated management approaches have considerable potential to improve outcomes. New oral anticoagulants that are easier to administer, require no, or much less, monitoring or dose-adjustment and have a favourable risk/benefit profile compared with conventional modalities, may offer an alternative with the potential to simplify VTE management. However, more information is required on practical management and the occurrence and treatment of bleeding complications. Increasing recognition of the burden of PE and new therapeutic modalities are altering the VTE management landscape in Pacific Asia. Consequently, there is a need to further raise awareness and bridge gaps between the latest evidence and clinical practice.en_US
dc.rightsMahidol Universityen_US
dc.titleTreating pulmonary embolism in Pacific Asia with direct oral anticoagulantsen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.